Perspectives

Rearchitecting the Rigid ERP Core. Why we co-led Doss's $55M Series B

Goodbye VLAs. Why we led Rhoda's Series A

CEO Series | Ikigai

CEO Series | Kriya Therapeutics: Building Generational Biotech

How Great Investors Spot Real Moats in AI

Premji Invest & Upscale AI Partnership

CEO Series | Runway: A new frontier for video generation

The Long Game: Building the Future of Premji Invest

The Anti-Exit Strategy: Premji Invest’s Approach to Evergreen Capital

Kriya Therapeutics: What if a single treatment could replace years of injections for millions?

Evolution’s Shortcuts, Engineered: Enveda’s Edge in Drug Discovery

Inference pricing is a race to the bottom. Why Baseten is different